Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (1983)
All Articles published online
|
Jul 14, 2006 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lodato F, Tamé MR, Colecchia A, Racchini C, Azzaroli F, D’Errico A, Casanova S, Pinna A, Roda E, Mazzella G. Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol 2006; 12(26): 4253-4255 [PMID: 16830387 DOI: 10.3748/wjg.v12.i26.4253] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i26/4253.htm |
| Number | Citing Articles |
| 1 |
Vincent Ho, Anna Mclean, Shaughan Terry. Severe Systemic Lupus Erythematosus Induced by Antiviral Treatment for Hepatitis C. JCR: Journal of Clinical Rheumatology 2008; 14(3): 166 doi: 10.1097/RHU.0b013e3181775e80
|
| 2 |
Rebecca L. Riding, Jillian M. Richmond, Keitaro Fukuda, John E. Harris. Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy. Pigment Cell & Melanoma Research 2021; 34(4): 683 doi: 10.1111/pcmr.12935
|
| 3 |
Jihad Slim, Muhammad Shoaib Afridi. Managing Adverse Effects of Interferon-Alfa and Ribavirin in Combination Therapy for HCV. Infectious Disease Clinics of North America 2012; 26(4): 917 doi: 10.1016/j.idc.2012.08.006
|
| 4 |
Manel Ramos-Casals. Viruses and lupus: the viral hypothesis. Lupus 2008; 17(3): 163 doi: 10.1177/0961203307086268
|
| 5 |
Rubina Rizvi, Mehrnaz Hojjati. Interferon-α Induced Lupus in a Patient With Chronic Hepatitis C Virus. JCR: Journal of Clinical Rheumatology 2011; 17(3): 152 doi: 10.1097/RHU.0b013e31821557e7
|
| 6 |
F. LODATO, S. BERARDI, A. GRAMENZI, G. MAZZELLA, M. LENZI, M. C. MORELLI, M. R. TAME, F. PISCAGLIA, P. ANDREONE, G. BALLARDINI, M. BERNARDI, F. B. BIANCHI, M. BISELLI, L. BOLONDI, M. CESCON, A. COLECCHIA, A. D’ERRICO, M. DEL GAUDIO, G. ERCOLANI, G. L. GRAZI, W. GRIGIONI, S. LORENZINI, A. D. PINNA, M. RAVAIOLI, E. RODA, C. SAMA, M. VIVARELLI. Clinical trial: peg‐interferon alfa‐2b and ribavirin for the treatment of genotype‐1 hepatitis C recurrence after liver transplantation. Alimentary Pharmacology & Therapeutics 2008; 28(4): 450 doi: 10.1111/j.1365-2036.2008.03761.x
|
| 7 |
Francesca Lodato, Francesco Azzaroli, Maria Rosa Tamè, Maria Di Girolamo, Federica Buonfiglioli, Natalia Mazzella, Paolo Cecinato, Enrico Roda, Giuseppe Mazzella. G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. World Journal of Gastroenterology 2009; 15(43): 5449-5454 doi: 10.3748/wjg.15.5449
|
| 8 |
Mónica Rodríguez Carballeira, Carmen De Juan, Joan Carles Reverter. Varón de 46 años con hematoma suprarrenal bilateral. Medicina Clínica 2008; 130(2): 71 doi: 10.1157/13115030
|
| 9 |
Zhipeng Zeng, Wei Tu, Bai Ji, Jie Liu, Kecheng Huang, Daan Nie, Liu Yang. IFN-α induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1223062
|
| 10 |
Nikroo Hashemi, Simona Rossi, Victor J Navarro, Steven K Herrine. Safety of peginterferon in the treatment of chronic hepatitis C. Expert Opinion on Drug Safety 2008; 7(6): 771 doi: 10.1517/14740330802423291
|
| 11 |
Cynthia M. Magro, Taylor Kalomeris, Christina R. Shreve, Julia T. Geyer, Sanjay S. Patel. Subcutaneous panniculitic-like T-cell lymphoma localized to a site of peginterferon alfa-2a administration. Leukemia & Lymphoma 2024; : 1 doi: 10.1080/10428194.2024.2310139
|
| 12 |
Sabrin Albeituni. Editorial: Towards a better understanding of hemophagocytic lymphohistiocytosis. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1385487
|